Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...

The expert panel looks to future treatment management for patients with myelodysplastic syndrome. Ryan Haumschild, PharmD, MS, MBA: I want to think about the future. How is the future changing? Dr ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...

DelveInsight's,“ Myelodysplastic Syndrome Pipeline Insights 2025” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of ...

report offers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU4 (Germany ...

Keros Therapeutics, Inc. (KROS) is gearing up to report long-term results from its phase 2 study using KER-050 [elritercept] for the treatment of patients with myelodysplastic syndrome [MDS]. Matter ...

Geron is planning to submit a New Drug Application (NDA) for imetelstat, a treatment for low to intermediate-1 risk myelodysplastic syndromes (MDS), in 2023 after favorable Phase 3 trial results.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...